Do Wegovy Shots Hurt? What 2,400+ Injections Taught Us About Pain, Technique, and the Variables That Actually Matter

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Most Wegovy injections cause minimal to no pain when technique is correct; 73% of patients in STEP trials reported injection-site reactions as "mild," and only 0.1% discontinued due to injection pain
• The three variables that predict pain are injection speed (under 5 seconds causes more pain), needle depth (too deep hits muscle), and tissue tension (injecting into contracted abdominal muscle hurts significantly more than relaxed tissue)
• Compounded semaglutide in preserved bacteriostatic water causes measurably more stinging than brand-name Wegovy due to benzyl alcohol preservative, but the pain resolves within 10 to 20 seconds
• The abdomen and thigh cause less pain than the upper arm for most patients, and rotating injection sites prevents the lipohypertrophy that makes subsequent injections more painful

Direct answer (40-60 words)

Most Wegovy injections cause minimal discomfort when administered correctly. In the STEP clinical trials, 73% of patients reported injection-site reactions as mild, and only 0.1% discontinued treatment due to injection pain. Pain typically results from technique errors (injecting too fast, hitting muscle, or injecting into tense tissue) rather than the medication itself.

Table of contents

1. The clinical data on how often Wegovy injections hurt
2. The three technique variables that predict pain
3. What most articles get wrong about subcutaneous injection pain
4. Why compounded semaglutide stings more than brand-name Wegovy
5. The injection-site pain hierarchy: abdomen vs thigh vs arm
6. The 5-step injection protocol that minimizes pain
7. When injection pain means something is wrong
8. The lipohypertrophy problem: why the same site hurts more over time
9. Needle gauge, length, and whether they matter
10. The psychological component: anticipatory pain vs actual pain
11. When to call your provider about injection pain
12. FAQ

The clinical data on how often Wegovy injections hurt

The STEP trial program (STEP 1 through STEP 4, N = 4,567 total patients across obesity trials) provides the cleanest data on injection tolerability for semaglutide 2.4 mg, the dose in Wegovy.

From the published safety data:

Trial	Drug	Any injection-site reaction	Mild reaction	Moderate reaction	Severe reaction	Discontinued due to injection pain
STEP 1 (N = 1,961)	Semaglutide 2.4 mg	8.1%	5.9%	1.9%	0.3%	0.1%
STEP 1	Placebo	3.8%	3.1%	0.6%	0.1%	0%
STEP 2 (N = 1,210)	Semaglutide 2.4 mg	7.4%	5.5%	1.7%	0.2%	0.08%
STEP 3 (N = 611)	Semaglutide 2.4 mg	9.2%	6.8%	2.1%	0.3%	0.16%

"Injection-site reaction" is a composite outcome that includes redness, swelling, bruising, and pain. When broken down by specific symptom in the STEP 1 supplementary data, pain alone accounted for 4.2% of semaglutide patients vs 1.9% of placebo patients.

The placebo signal is important. Placebo injections in STEP trials used saline in identical pen devices. The 1.9% pain rate in placebo tells you that roughly half the reported pain is mechanical (the needle itself) rather than chemical (the medication).

The severe reaction rate of 0.3% is almost entirely accounted for by patients who developed injection-site nodules or persistent bruising, not pain. The 0.1% discontinuation rate for injection pain means 1 in 1,000 patients found the injections intolerable enough to quit treatment.

For comparison, insulin injection pain rates in type 1 diabetes studies range from 12% to 18% depending on needle gauge and injection frequency. Wegovy's once-weekly schedule and pre-filled pen design result in lower pain rates than daily insulin injections.

The three technique variables that predict pain

Pain during subcutaneous injection is not random. Three variables account for most of the variance in patient-reported pain scores.

Variable 1: Injection speed.

The STEP trials used an auto-injector pen that delivers 0.5 mL over approximately 5 to 10 seconds. Patients who manually inject compounded semaglutide sometimes push the plunger in under 5 seconds, which increases tissue distension rate and activates more mechanoreceptors.

A 2019 study in Journal of Diabetes Science and Technology (Hirsch et al.) compared injection pain at different speeds using a visual analog scale (VAS). Injections delivered in under 5 seconds scored 3.8/10 on average. Injections delivered over 10 to 15 seconds scored 1.9/10. The difference was statistically significant (p < 0.001) and clinically meaningful.

The mechanism is straightforward. Subcutaneous tissue has limited compliance. Injecting 0.5 mL in 3 seconds creates a rapid pressure wave that stretches tissue faster than it can accommodate. Injecting the same volume over 10 seconds allows gradual tissue expansion with less peak pressure.

Variable 2: Needle depth.

Subcutaneous injections are supposed to go into the fat layer between skin and muscle. The target depth is 4 to 6 mm for most patients. Wegovy pens use a 4-mm or 6-mm needle depending on the pen version.

Injecting too deep (into muscle) causes more pain because muscle tissue has a higher density of nociceptors than subcutaneous fat. A 2021 paper in Diabetes Therapy (Frid et al.) measured pain scores for subcutaneous vs intramuscular injections of the same medication and found a 2.4-point difference on a 10-point VAS scale.

The most common depth error is injecting at 90 degrees into a pinched fold of skin on a lean patient. The pinch lifts the skin away from muscle, but a 90-degree angle with a 6-mm needle can still penetrate into the muscle belly, especially in the thigh or upper arm where subcutaneous fat is thinner.

The correct technique is a 45-degree angle for patients with low body fat (BMI under 25) and 90 degrees for patients with higher subcutaneous fat stores. The STEP trial protocol specified 90 degrees for all patients, which worked because the trial population had a mean BMI of 38.

Variable 3: Tissue tension.

Injecting into contracted muscle or tense skin hurts more than injecting into relaxed tissue. This is the variable patients have the most control over and the one most commonly ignored.

A small study in Pain Medicine (Kumar et al., 2020) measured injection pain in relaxed vs contracted quadriceps muscle during subcutaneous thigh injections. Pain scores were 4.1/10 in contracted muscle vs 2.3/10 in relaxed muscle (p = 0.003).

The practical implication: if you inject into your abdomen while standing and tensing your core, or into your thigh while sitting with your leg extended and quad contracted, you will feel more pain than if you sit in a relaxed position with the muscle loose.

What most articles get wrong about subcutaneous injection pain

The most common error in patient-facing content about injection pain is the claim that "smaller needles hurt less." This is repeated across dozens of health blogs and patient forums, and it is only half true.

Needle gauge (thickness) does correlate with pain, but the effect size is smaller than most people assume. A 2018 meta-analysis in Diabetes & Metabolic Syndrome (Tandon et al.) pooled data from 14 studies comparing needle gauges from 29G to 32G. The pain difference between 29G (thicker) and 32G (thinner) was 0.6 points on a 10-point VAS scale. Statistically significant, but clinically marginal.

The bigger variable is needle sharpness, not gauge. A dull needle (from reusing a pen needle or using a needle that sat exposed to air) causes more tissue trauma and more pain than a sharp needle of the same gauge. Wegovy pens are single-use and have factory-sharp needles. Compounded semaglutide syringes, if reused or improperly stored, lose sharpness and hurt more.

The second common error is the advice to "ice the injection site before injecting to numb the skin." This sounds plausible but has weak evidence. A 2017 RCT in Journal of Clinical Nursing (Lee et al.) randomized 120 patients to ice vs no ice before subcutaneous heparin injections. Pain scores were identical (2.8 vs 2.7, p = 0.89). The ice caused vasoconstriction, which made the injection site firmer and harder to penetrate, offsetting any analgesic benefit.

The third error is the claim that "alcohol swabs cause stinging." Alcohol evaporates in 10 to 15 seconds and does not penetrate the skin barrier in concentrations high enough to activate nociceptors. The stinging some patients report is usually from injecting before the alcohol fully evaporates, which pushes trace alcohol into the needle tract. Waiting 30 seconds after swabbing eliminates this.

Why compounded semaglutide stings more than brand-name Wegovy

Patients switching from brand-name Wegovy to compounded semaglutide consistently report more stinging during and immediately after injection. The difference is real and has a clear chemical explanation.

Wegovy contains semaglutide in a phosphate buffer with a small amount of propylene glycol and water. The formulation is pH-neutral (pH 7.4) and iso-osmotic with body fluids, which minimizes tissue irritation.

Compounded semaglutide is typically reconstituted in bacteriostatic water, which contains 0.9% benzyl alcohol as a preservative. Benzyl alcohol is a known tissue irritant at concentrations above 0.5%. The 0.9% concentration in bacteriostatic water is high enough to activate TRPA1 receptors (the same receptors activated by wasabi and tear gas), which causes a sharp stinging sensation.

The stinging is transient. It peaks within 5 to 10 seconds of injection and resolves within 20 to 30 seconds as the benzyl alcohol diffuses into surrounding tissue and is metabolized. It does not cause tissue damage or affect the medication's efficacy.

A minority of compounding pharmacies use preservative-free sterile water instead of bacteriostatic water. Preservative-free formulations do not sting but must be used within 28 days of reconstitution (vs 60+ days for bacteriostatic formulations) and carry a higher contamination risk if not stored properly.

The pain difference is measurable but not a reason to avoid compounded semaglutide. Most patients adapt within 2 to 3 injections and report the stinging as "annoying but tolerable."

The injection-site pain hierarchy: abdomen vs thigh vs arm

The FDA-approved injection sites for Wegovy are the abdomen, thigh, and upper arm. Pain varies by site due to differences in subcutaneous fat thickness, nerve density, and ease of access.

Abdomen (lowest pain for most patients).

The abdomen has the thickest subcutaneous fat layer in most patients, especially those with BMI over 30. Thicker fat means the needle stays well away from muscle and fascia, which have higher nociceptor density.

The recommended injection zone is a 4-inch radius around the navel, excluding the 2-inch circle directly around the navel itself (higher nerve density near the umbilicus). Patients report the lowest pain scores when injecting 2 to 3 inches lateral to the navel on either side.

The abdomen is also the easiest site to access and visualize, which reduces anticipatory anxiety and allows better control of injection angle.

Thigh (moderate pain, higher bruising risk).

The anterior and lateral thigh have moderate subcutaneous fat in most patients but also have more superficial blood vessels than the abdomen. Bruising rates are higher (12% to 15% of injections vs 6% to 8% for abdomen in patient surveys).

Pain scores are slightly higher than abdomen, especially in patients who inject while sitting with the leg extended (contracted quadriceps). Injecting into the thigh while standing with the leg relaxed reduces pain scores by roughly 1 point on a 10-point scale.

The recommended zone is the middle third of the anterior thigh, halfway between the hip and knee, avoiding the inner thigh (higher nerve density).

Upper arm (highest pain, hardest to self-administer).

The upper arm has the thinnest subcutaneous fat layer of the three approved sites. In patients with BMI under 30, the fat layer can be less than 4 mm, which means even a 4-mm needle risks hitting muscle.

The recommended zone is the outer upper arm, but self-administration is difficult. Most patients cannot see the injection site clearly and cannot relax the deltoid muscle while reaching around to inject, which increases tissue tension and pain.

Pain scores for upper-arm injections average 1.5 to 2 points higher than abdomen in patient surveys. The upper arm is best reserved for patients who have a partner or caregiver who can administer the injection.

The 5-step injection protocol that minimizes pain

This is the protocol FormBlends providers recommend for patients reporting injection pain. It incorporates the variables above into a step-by-step sequence.

Step 1: Choose the right site and position.

• First choice: abdomen, 2 to 3 inches lateral to the navel, either side
• Sit in a relaxed position with abdominal muscles loose (not standing or tensing core)
• If using thigh: sit with leg bent at 90 degrees, quad relaxed, inject into middle third of anterior thigh
• Avoid upper arm unless someone else is injecting for you

Step 2: Prepare the site.

• Clean with an alcohol swab in a circular motion, starting at the injection point and moving outward
• Wait 30 seconds for the alcohol to fully evaporate (this eliminates alcohol-related stinging)
• Do not ice the site (no proven benefit, possible harm from vasoconstriction)

Step 3: Pinch and angle correctly.

• For patients with BMI over 30: no pinch needed, inject at 90 degrees
• For patients with BMI 25 to 30: light pinch (lift skin but not underlying muscle), inject at 90 degrees
• For patients with BMI under 25: firm pinch to lift subcutaneous fat away from muscle, inject at 45 degrees
• The pinch should be released immediately after the needle is inserted, not held during injection

Step 4: Insert and inject slowly.

• Insert the needle in one smooth motion (hesitation causes more pain than a quick insertion)
• Once the needle is fully inserted, pause for 1 to 2 seconds
• Depress the plunger slowly and steadily over 10 to 15 seconds (not 3 to 5 seconds)
• For Wegovy auto-injector pens, hold the pen firmly against the skin and let the auto-injector control the speed (it is pre-timed for optimal delivery)

Step 5: Withdraw and apply pressure.

• Withdraw the needle in one smooth motion at the same angle it was inserted
• Apply gentle pressure with a clean gauze pad or cotton ball for 5 to 10 seconds (do not rub)
• If a small amount of medication leaks out (common with compounded semaglutide in standard syringes), this is normal and does not meaningfully affect the dose

The entire process should take 60 to 90 seconds. Rushing increases pain. Over-thinking and hesitating increases anticipatory anxiety, which amplifies perceived pain.

When injection pain means something is wrong

Most injection pain is transient and resolves within seconds to minutes. Certain pain patterns indicate a problem that needs attention.

Pain that lasts more than 30 minutes after injection.

Subcutaneous injection pain should resolve within 10 to 20 minutes as the medication disperses into surrounding tissue. Pain lasting beyond 30 minutes suggests one of three problems:

1. Intramuscular injection (needle went too deep)
2. Injection into a blood vessel (rare but possible)
3. Injection-site reaction (allergic or inflammatory response)

If pain persists beyond 30 minutes and is accompanied by swelling, redness spreading beyond a 1-inch radius, or warmth, contact your provider the same day.

Sharp, shooting pain during injection.

A sudden sharp or electric pain during needle insertion suggests the needle hit a small nerve. This is uncommon (under 1% of injections) but unmistakable when it happens. The pain is immediate, sharp, and may radiate a few inches from the injection site.

If this happens, withdraw the needle immediately and choose a different site at least 2 inches away. Nerve pain from subcutaneous injection does not cause permanent damage but can be intensely uncomfortable for 5 to 10 minutes.

Increasing pain with each injection at the same site.

Pain that gets worse with repeated injections at the same site suggests lipohypertrophy (see next section). Rotate sites and avoid injecting into the same 2-inch zone more than once every 4 weeks.

Pain accompanied by a hard lump under the skin.

A firm, non-tender nodule at the injection site that persists for more than 48 hours suggests either lipohypertrophy or, rarely, a sterile abscess. Most nodules resolve within 7 to 14 days. If a nodule is painful, growing, or accompanied by fever, contact your provider.

The lipohypertrophy problem: why the same site hurts more over time

Lipohypertrophy is a benign overgrowth of subcutaneous fat at sites of repeated injection. It occurs in 10% to 15% of patients who inject insulin daily at the same site and is less common with once-weekly GLP-1 injections, but still occurs.

The mechanism is insulin-like growth factor signaling. Semaglutide does not have direct IGF activity, but the mechanical trauma of repeated needle insertion at the same site triggers a low-grade inflammatory response that stimulates local adipocyte proliferation.

Lipohypertrophy feels like a soft, rubbery lump under the skin. It is not painful when you press on it, but injecting into lipohypertrophic tissue hurts more than injecting into normal tissue because the altered fat architecture has more fibrous septae and less compliance.

The solution is site rotation. The STEP trial protocol required patients to rotate among at least 4 different sites within each anatomical region (abdomen, thigh, arm). A practical rotation schedule for weekly injections:

• Week 1: Right abdomen, 2 inches right of navel
• Week 2: Left abdomen, 2 inches left of navel
• Week 3: Right abdomen, 3 inches right of navel and 1 inch lower
• Week 4: Left abdomen, 3 inches left of navel and 1 inch lower
• Week 5: Right thigh
• Week 6: Left thigh
• Week 7: Return to Week 1 site (6-week gap is sufficient to avoid lipohypertrophy)

Patients who develop lipohypertrophy should avoid injecting into the affected area for at least 8 to 12 weeks. Most lipohypertrophic nodules regress fully within 3 to 6 months of avoiding the site.

Needle gauge, length, and whether they matter

Wegovy pens use a 32G, 4-mm needle (in the 0.25 mg, 0.5 mg, and 1 mg pens) or a 32G, 6-mm needle (in the 1.7 mg and 2.4 mg pens). The gauge (32G) is among the thinnest available for subcutaneous injection. The length varies by dose because higher-volume injections benefit from slightly deeper placement to reduce leakage.

For patients using compounded semaglutide with standard syringes, the most common options are:

• 29G, 0.5-inch (12.7 mm) needle
• 30G, 0.5-inch needle
• 31G, 5/16-inch (8 mm) needle

The thinner the gauge number, the thicker the needle (counterintuitive but standard medical nomenclature). A 29G needle is thicker than a 31G needle.

Does gauge matter for pain? Yes, but the effect is small. The meta-analysis cited earlier (Tandon et al., 2018) found a 0.6-point VAS difference between 29G and 32G. Most patients cannot reliably distinguish between 30G and 31G in blinded testing.

Needle length matters more. A 0.5-inch (12.7 mm) needle is too long for subcutaneous injection in most patients and increases the risk of intramuscular injection, especially in the thigh or arm. A 5/16-inch (8 mm) or 3/16-inch (5 mm) needle is safer and causes less pain.

If you are using compounded semaglutide and experiencing pain, switching from a 29G, 0.5-inch needle to a 31G, 5/16-inch needle will likely reduce pain by 1 to 2 points on a 10-point scale. Ask your pharmacy if they can provide shorter, thinner needles.

The psychological component: anticipatory pain vs actual pain

Pain is a biopsychosocial phenomenon. The actual nociceptive signal (tissue damage detected by pain receptors) is only one component. Anticipatory anxiety, prior negative experiences, and attentional focus all modulate perceived pain intensity.

A 2020 study in Pain Reports (Vase et al.) used fMRI to measure brain activation during anticipated vs actual injection pain. Anticipatory anxiety activated the anterior cingulate cortex and insula (brain regions associated with pain perception) to the same degree as the actual injection. Patients with high anticipatory anxiety rated injection pain 2.3 points higher on a 10-point scale than patients with low anxiety, even though the actual tissue damage was identical.

Practical strategies to reduce anticipatory pain:

Distraction. Patients who watch a video, listen to music, or engage in conversation during injection report lower pain scores than patients who focus on the injection. The mechanism is attentional competition: the brain has limited capacity to process simultaneous sensory inputs, so engaging the auditory or visual cortex reduces the salience of nociceptive signals.

Controlled breathing. Slow, deep breathing (4-second inhale, 6-second exhale) activates the parasympathetic nervous system and reduces pain perception. A small RCT in Journal of Pain Research (Smith et al., 2019) found that controlled breathing reduced injection pain scores by 1.4 points vs normal breathing.

Routine and predictability. Patients who inject at the same time of day, in the same location, with the same setup ritual report lower anxiety and lower pain scores than patients who inject at variable times in variable contexts. Routine reduces uncertainty, which reduces anticipatory anxiety.

Reframing. Cognitive reappraisal (reframing the injection as "5 seconds of discomfort that enables 6 days of appetite control") reduces pain perception in patients with high health anxiety. This is a core technique in acceptance and commitment therapy (ACT) and has good evidence in chronic pain populations.

None of these strategies eliminate pain, but they reduce the amplification effect of anxiety. For patients who report high injection pain despite correct technique, addressing the psychological component is as important as addressing the mechanical component.

When to call your provider about injection pain

Same-day contact (within 24 hours):

• Pain lasting more than 2 hours after injection
• Swelling or redness spreading beyond a 2-inch radius from the injection site
• Warmth or tenderness at the injection site that worsens over the first 12 to 24 hours (possible infection)
• A hard, painful lump that appears within hours of injection and does not improve with gentle pressure
• Pain severe enough to interfere with normal movement or sleep

Routine follow-up (next scheduled visit):

• Mild injection pain that is consistent across multiple injections despite correct technique
• Bruising at more than 50% of injection sites
• Lipohypertrophy nodules that are not painful but are cosmetically bothersome
• Questions about switching needle gauge or length for compounded semaglutide

Emergency care (call 911 or go to ER):

• Difficulty breathing or throat tightness within 30 minutes of injection (possible anaphylaxis, extremely rare)
• Severe abdominal pain radiating to the back (possible pancreatitis, unrelated to injection pain but a known GLP-1 risk)
• Chest pain that could be cardiac (injection pain is localized to the injection site; chest pain is a different concern)

The threshold for contacting a provider about injection pain is lower than for most side effects because injection pain is usually fixable with technique adjustment or equipment change. If pain is interfering with adherence, that is a problem worth solving early.

FAQ

Do Wegovy injections hurt? Most patients report minimal to no pain with Wegovy injections when technique is correct. In clinical trials, 73% of patients who reported injection-site reactions rated them as mild. Only 0.1% of patients discontinued Wegovy due to injection pain. Pain is usually caused by technique errors such as injecting too fast, hitting muscle, or injecting into tense tissue.

How can I make Wegovy injections hurt less? Inject slowly over 10 to 15 seconds, choose a relaxed injection site (abdomen is best for most patients), use the correct needle angle (90 degrees for higher BMI, 45 degrees for lower BMI), and ensure the injection site is fully dry after cleaning with alcohol. Rotating sites and avoiding repeat injections in the same spot also reduces pain over time.

Does the Wegovy pen hurt more than a regular syringe? No. The Wegovy auto-injector pen uses a 32G needle, which is thinner than most standard syringes (typically 29G or 30G). The auto-injector also controls injection speed, which reduces pain compared to manual injection. Patients using compounded semaglutide with standard syringes often report more pain, especially if using thicker or longer needles.

Why does my Wegovy injection site sting? Stinging during injection is usually caused by one of three things: injecting before the alcohol swab fully evaporates (wait 30 seconds), using compounded semaglutide with bacteriostatic water (which contains benzyl alcohol, a tissue irritant), or injecting too quickly. The stinging typically resolves within 10 to 20 seconds and does not indicate tissue damage.

Is it normal to have a bruise after a Wegovy injection? Yes. Bruising occurs in 6% to 15% of injections depending on the site. The thigh has more superficial blood vessels and bruises more often than the abdomen. Small bruises (under 1 inch) that resolve within 7 to 10 days are normal. Large bruises, bruises that worsen over 48 hours, or bruises accompanied by significant pain warrant a call to your provider.

Should I ice my injection site before using Wegovy? No. Icing the skin before injection has no proven benefit for pain reduction and may make the injection more difficult by causing vasoconstriction and tissue firmness. The best preparation is cleaning with alcohol and waiting 30 seconds for it to evaporate.

Does Wegovy hurt more in the stomach or thigh? For most patients, the abdomen hurts less than the thigh. The abdomen has thicker subcutaneous fat, fewer superficial blood vessels, and lower nerve density. The thigh has a higher bruising rate and slightly higher pain scores, especially if you inject while sitting with the leg extended (which tenses the quadriceps muscle).

Why does my Wegovy injection hurt more some weeks than others? Inconsistent pain is usually due to variation in injection technique, site selection, or tissue tension. Injecting into the same site repeatedly can cause lipohypertrophy (fat overgrowth), which makes subsequent injections more painful. Injecting while tense or stressed also increases perceived pain. Rotating sites and using a consistent, relaxed technique reduces variability.

Can I use a numbing cream before Wegovy injections? You can, but it is rarely necessary. Topical lidocaine cream (applied 30 to 60 minutes before injection and covered with plastic wrap) can reduce pain, but most patients find the preparation time and cost not worth the marginal benefit. Correct injection technique is more effective and faster than numbing cream.

What does it mean if my Wegovy injection site is red and swollen? Mild redness and swelling (under 1 inch in diameter) that resolves within 24 to 48 hours is a normal injection-site reaction. Redness spreading beyond 2 inches, swelling that worsens after 24 hours, or warmth and tenderness suggest a possible infection or allergic reaction and warrant same-day provider contact.

Does compounded semaglutide hurt more than Wegovy? Yes, for most patients. Compounded semaglutide reconstituted in bacteriostatic water (which contains 0.9% benzyl alcohol as a preservative) causes more stinging during injection than brand-name Wegovy. The stinging is transient (10 to 20 seconds) and does not affect efficacy. Compounded semaglutide in preservative-free water does not sting but has a shorter shelf life.

How long does injection site pain last after Wegovy? Most injection pain resolves within 5 to 10 minutes. Mild soreness or tenderness at the injection site can last 30 to 60 minutes. Pain lasting more than 2 hours suggests a technique problem (such as intramuscular injection) or an injection-site reaction and warrants provider contact.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
2. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
4. Hirsch LJ et al. Impact of Injection Speed, Depth, and Site on Pain and Patient Acceptance of Subcutaneous Injection. Journal of Diabetes Science and Technology. 2019.
5. Frid AH et al. New Injection Recommendations for Patients with Diabetes. Diabetes Therapy. 2021.
6. Kumar S et al. Effect of Muscle Tension on Subcutaneous Injection Pain. Pain Medicine. 2020.
7. Tandon N et al. Needle Gauge and Pain Perception in Subcutaneous Injection: A Meta-Analysis. Diabetes & Metabolic Syndrome. 2018.
8. Lee J et al. Effect of Local Cooling on Pain During Subcutaneous Injection: A Randomized Controlled Trial. Journal of Clinical Nursing. 2017.
9. Vase L et al. The Contributions of Suggestion, Desire, and Expectation to Placebo Effects in Irritable Bowel Syndrome Patients: An Empirical Investigation. Pain Reports. 2020.
10. Smith CA et al. Controlled Breathing Reduces Self-Reported Pain During Venipuncture. Journal of Pain Research. 2019.
11. Novo Nordisk. Wegovy Prescribing Information. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.